Newgrange Consultants work with their clients to assess current leadership capabilities and to objectively evaluate development potential. We work with our clients to configure assessment processes appropriate to business circumstances and leadership selection and development scenarios including
- With investors, for pre-investment selection decisions and post-investment leadership development
- CEO, C-suite member, and senior executive effectiveness in current role
- Assessments for first time CEO appointments, including alignment to the chair, the board and the leadership team
- Assessment processes to support assessments across leadership teams
- Assessment of high potential emerging talent and future leaders for growth roles and development projects
- With investors, for pre-investment selection decisions and post-investment leadership development
- CEO, C-suite member, and senior executive effectiveness in current role
- Assessments for first time CEO appointments, including alignment to the chair, the board and the leadership team
- Assessment processes to support assessments across leadership teams
- Assessment of high potential emerging talent and future leaders for growth roles and development projects
No data available
North Highland is the leading change and transformation consultancy providing management consulting services to the Fortune 1000 for over 30 years. Our industry practice teams work with the top global Life sciences companies in achieving their goals, from early-stage development, to manufacturing, supply chain, and commercialization. We provide consulting solutions across an array of industry challenges including enterprise transformation, digital & data science, workforce strategies, and omnichannel effectiveness. We bring a strong, collaborative team of experts to drive rapid value realization focused on rising above disruption and delivering business transformation. https://www.northhighland.com/
No data available
Nuclera is a US and UK-based biotechnology company driven by the mission to better human health by making proteins accessible. Nuclera is enabling life science researchers to obtain active proteins from DNA in 48 hours through its benchtop eProtein DiscoveryTM platform.
Website: https://www.nuclera.com
Contact: hello@nuclera.com
Watch our showcase video: https://www.nuclera.com/resource-library/video-intro-to-eprotein-discovery/
Website: https://www.nuclera.com
Contact: hello@nuclera.com
Watch our showcase video: https://www.nuclera.com/resource-library/video-intro-to-eprotein-discovery/
Heptares creates new medicines targeting previously undruggable or challenging GPCRs, a superfamily of receptors linked to many diseases. We are pioneering a structure-based drug design approach to GPCRs, leveraging proprietary technologies for protein stabilisation, structure determination, and fragment-based discovery. Our partners include Shire, AstraZeneca, MedImmune and Takeda. Our objective is to build a broad pipeline of novel medicines to transform the treatment of serious diseases, including Alzheimer’s disease, Parkinson’s disease, schizophrenia, depression, chronic insomnia, addiction, migraine and diabetes.
No data available
No data available
OMass Therapeutics is a drug discovery company exploiting novel mass spectrometry platforms to develop therapeutics against challenging disease targets.?
No data available